Get started

Smallcap

GSI.V Video systems for smart cities; essential business statusStrong accumulation. Bullish MACD cross. Bullish Stoch/RSI action. I am in at .15. --------------------------------------------------------------------------------------------------------------------- Gatekeeper Operating as Essential Business During COVID-19 Outbreak Abbotsford, BC - TheNewswire - April 6, 2020 - Gatekeeper Systems Inc. (‘Gatekeeper’ or the ‘Company’) (TSXV:GSI) (OTC:GKPRF) (FSE:1GK) a leading provider of intelligent video solutions for public transport and smart cities, provides a corporate update relating to its operations during the COVID-19 outbreak. Gatekeeper, through its subsidiary Gatekeeper Systems USA Inc., has been deemed an essential business during the emergency order which temporarily prohibits operation of non-essential businesses in Pennsylvania. The Company’s business relating to the Southeastern Pennsylvania Transportation Authority (SEPTA) continues normal operations. SEPTA is the Company’s largest customer and represented approximately 30% of the Company’s revenues during its 2019 fiscal year. The Company reports no material change in its contract with SEPTA announced on October 17, 2019 to provide annually recurring services valued at approximately $2.36 million per year. The Company reports no material change in its contract with SEPTA announced on October 9, 2019 to supply and install digital video recorders on SEPTA vehicles and trains in a contract valued at approximately $6.3 million. This contract is expected to be billed during the second half of the Company’s fiscal year which ends August 31, 2020. Gatekeeper has adjusted its business operations during the COVID-19 outbreak to firstly ensure the safety of its employees as its top priority. Protection procedures for service technicians have been implemented and office employees are working from home where possible. The Company is also working with its suppliers and customers during this period of business disruption to ensure continuity of business operations where possible. The Company will report its financial results for its second quarter ended Feb 29, 2020 by the prescribed filing due date of April 29, 2020. Gatekeeper also announces that it has granted an aggregate of 675,000 incentive stock options to certain directors, officers, employees and consultants under the Company’s stock option plan, subject to regulatory approval. The stock options are exercisable at a price of $0.135 for a period of five years from the date of grant and subject to vesting provisions.
TSXV:GSILong
by wealth_bakery
AGN.C -- Coronavirus Treatment Spec; Phase 2 Clinical Trial newsAnother CoronaVirus spec play. Pulled back from recent highs and trading in the support band, for now. I bought in at .20 - .21 today. $18M mkt cap. 90M float. Could see a nice run on today's news: Algernon to Support Planned Phase 2 Trial of Ifenprodil for Coronavirus VANCOUVER, British Columbia, March 19, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Novotech, a leading Asia-Pacific clinical research organization (CRO), has identified physicians in South Korea who have agreed to conduct an investigator initiated phase 2 clinical trial of Ifenprodil for coronavirus patients. The investigators were identified after Algernon retained Novotech to conduct a feasibility study in South Korea. Novotech was asked to advise on the most efficient regulatory approach to initiating a phase 2 clinical trial for Ifenprodil for COVID-19 and to also help identify potential investigators. Ifenprodil is an already approved drug in South Korea and Japan for certain neurological conditions with a known safety history. Algernon has been investigating Ifenprodil under its re-purposed drug program and has appointed Novotech as the lead CRO for its upcoming idiopathic pulmonary fibrosis (IPF) and chronic cough phase 2 clinical trial to be conducted in Australia. The Company is in the process of refining the protocol for the phase 2 coronavirus study after receiving input from the investigators, and is working with Novotech to provide the necessary information and support in order to assist with the study’s approval. The study approval process may be expedited due to the current global health crisis. The Company will release more information about the planned phase 2 coronavirus study shortly. The decision to retain Novotech to conduct a feasibility study was made after a recent independent study found that Ifenprodil significantly reduced acute lung injury (ALI) and improved survivability in an animal study with Asian H5N1 infected mice by 40%. Asian H5N1 is the most lethal form of influenza known to date with an over 50% mortality rate. The drug was also previously shown in a separate study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function. “This independent study data, along with the data generated from the Company’s animal studies on IPF and chronic cough, have supported the Company’s recent new COVID-19 and acute lung injury clinical program,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
CSE:AGNLong
by wealth_bakery
LBL.V -- Stem cell based CoronaVirus treatment; VOLUME!LBL.V is hitting highest volume on TSX-V today. Very similar setup to VXL.V from last week, just before it made the big move from .14 to .325 but cheaper and much better financials. Cash flow positive. $8.4M market cap. 93M shares out. See the most recent news release with regards to positive outcomes in applying their technology to treat the Coronavirus patients in China: "Recently published results from an investigator-initiated clinical study conducted in China which reported that allogeneic mesenchymal stem cells (MSCs) cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia." Google "Lattice Biologics to Evaluate Anti-Inflammatory Stem Cell Therapy Treatment of COVID-19 Lung Disease"
LLong
by wealth_bakery
1
YouGov - Correction over, new highs expected.Buy YouGov (YOU.L) YouGov plc is a United Kingdom-based international data and analytics company. The Company’s suite of products and services is made up of syndicated data products including YouGov BrandIndex and YouGov Profiles and data services including YouGov Omnibus and YouGovCustom Research. YouGov BrandIndex is a daily brand perception tracker. YouGov Profiles is its planning and segmentation tool. YouGov Omnibus finds out people's opinions, attitudes and behaviors. YouGov Custom Research conducts quantitative and qualitative research. The company has 35 offices in 22 countries. Market Cap: £546Million YouGov is trading in a fantastic long-term uptrend. The shares have recently corrected from fresh all-time highs at 616p and appear to have found some support at the uptrend support line. The shares are on the move higher today, the close above the 10EMA could be a sign that the corrective move lower has come to an end and that further upside can be expected over the medium to long term. We are targeting a move to fresh all-time highs at 700p. Stop: 504p Target: 700p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
LSE:YOULong
by Investamate
EW.V -- Low risk bottom fishing opp; trading at cash valueAn incredible opportunity to buy EW.V at cash value. With JV partner in Romania covering 100% of the exploration costs, this could become a multi-bagger if any of the wells being tested are deemed commercial. EW.V is getting 15% of any oil that spuds. The stock has found a bottom at .055 in the past 2 weeks with bid support steadily increasing. Bullish divergence with MACD/RSI/Stochastic indicators points to a likely near-term breakout. I am long at .055 - .065. ASSETS Cash: $3,719,020 GST Receivable: $7,923 Amounts Receivable: $223,772 Prepaid Expenses: $22,654 Investments: $554,709 Assets Held For Sale: $2,067,867 Total Assets: $6,595,945 LIABILITIES Accounts Payable: $206,404 Decommissioning Liability: $309,904 Liabilities On Asset Held For Sale: $943,472 Deposit: $65,505 Total Liabilities: $1,525,285 NAV $6,595,945 - $1,525,285 = $5,070,660
TSXV:EWLong
by wealth_bakery
ESPT.V On Watch for Downtrend Pattern Breakout (eSports/Gaming)ESPT.V lit up a nice green candle on the daily chart to end the week. Poked its head above the downtrend channel that started on Aug 20th for the first time. The company is one of the early movers in the rapidly growing #eSports sector and is expected to close a revenue-generating acquisition within 1 - 2 weeks, followed by another major acquisition. Both were paid in .30 shares. Currently trading at .225. Very bullish macro environment. Latest RBC Wealth Management report shows #Gaming #eSports sectors are in the early bull cycle. ESPT.V is one of the better values with $2.3M in revenues last year, $9M mkt cap and 43M float. Catchy ticker name is a bonus. :)
ELong
by wealth_bakery
48North - The Small Cap Cannabis Company To WatchI have maintained a long thesis on 48North Cannabis Corporation since October 2018, and the trade worked wonderfully into March of last year. However, 48North pulled back alongside the entire cannabis sector, and rightfully so on some of their own missteps. As a brief introduction, I believe 48North's competitive advantage stems from their outdoor grow operation, creating a low cost of goods operating model that will enable 48North to price products competitively and reward investors with higher gross margin performance when compared against the peer group. It should be noted that 48North missed their production guidance for 2019- resulting from delayed licensing for drying rooms. In 2019 48North demonstrated that outdoor grown cannabis can be completed at scale, at a low cost, and successfully pass Health Canada's quality control standards. From a chart perspective I'm considering the Elliott Wave ABC pattern to be completed with a clean retracement & double bottom at $0.315 - neatly correlating with the 161.8 fib extension of Wave A Current Market Cap: $63M Cash on Hand: $40M It is my opinion that 48North's cash position reduces the need for any capital injection through 2020. Frankly- it is going to be in the hands of 48North to demonstrate in 2020 that they truly can achieve their projected outdoor harvest numbers with drying capacity not being a barrier in 2020.
NLong
by tomthetrader1
8
Trans-Siberian Gold - Breaking from a wedgeBuy Trans-Siberian Gold (TSG.L) Trans-Siberian Gold plc is a United Kingdom-based resource company engaged in acquiring and developing a portfolio of gold mining assets in Russia. The Company's subsidiary, ZAO Trevozhnoye Zarevo (TZ), holds approximately 20 square kilometers of mining license in the southern part of the Kamchatka peninsula, including the Asacha gold deposit, an epithermal gold/silver deposit located on a tertiary volcanic arc typical of ore systems found along the Pacific Rim. The main ore zone at Asacha consists of approximately five steeply dipping veins with over two principal veins averaging over two meters in width. Market Cap: £90.21Million The Trans-Siberian share price has been steadily increasing since the beginning of 2019. The shares reached new all-time highs at 133p before correcting sharply. The corrective move lower has stalled around the 50% Fibonacci level at 90.5p. The consolidation has formed a wedge on the daily chart, which has now broken to the upside. We believe this could lead to continuation higher in the short to medium term. Stop: 90p Target 1: 133p Target 2: 150p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
TLong
by Investamate
Pan African Resources - Digging for goldBuy Pan African Resources (PAF.L) Pan African Resources PLC is a precious metals producer engaged in mining. The Company operates through six segments: Barberton Mines, located in Barberton South Africa, derives revenue from sale of gold to South African financial institutions; Evander Gold Mining Proprietary Limited and Evander Gold Mines Limited (collectively known as Evander Mines), located in Evander South Africa, derives revenue from sale of gold to South African financial institutions; Phoenix Platinum, located in North West province in South Africa, derives revenue from sale of platinum group element concentrate to Western Platinum Limited. Market Cap: £224.46Million Pan African Resources is trading in a sequence of higher highs and higher lows since July 2018. The shares topped out in August at 14.7p and have since corrected sharply lower. The correct move has stalled just in front of the 61.8% Fibonacci support level at 10.86p and now appears to be forming a wedge pattern. The move above resistance at 11.76p has confirmed the break of the wedge, which we believe could lead to more upside in the short to medium term. Stop: 10.7p Target 1: 14.7p Target 2: 17.5p Interested in UK Small Caps? Join our free Telegram channel for up to date analysis on the best small-cap opportunities in the UK right now. t.me
LSE:PAFLong
by Investamate
JWCA:TSXV - James E Wagner Cultivation: potentially bottomingJWCA:TSXV - James E Wagner Cultivation: after breaking down from the 80c range it was trading in for a couple weeks JWCA has so far found support just above a previous consolidation zone from mid January. watching for a move up above 76c and 80c as potential confirmation. The MJ sector is currently weak still and despite positive news today from their JWC2 facility, it was not able to hold any gains. Price action remains stuck under the 50dma & 200dma, with a potential death cross coming this week on the two averages. While these indicators are not in a bullish setup, I remain long term bullish on the stock. Near term catalysts: first harvest from phase 1 JWC2 facility which will represent their first harvest for recreational use greatly expanding revenue. Just announced JULY 2 that they doubled the capacity at JWC2, with the next phase getting licensed from Health Canada and will be into production ASAP. My opinion is this little LP has some great IP in their Growth Storm Technology as well as great quality cannabis and is significantly under valued relative to peers on a capacity basis yet which tend to have lesser quality cannabis.
J
by justin_paul
3